Vicodin, the once-ubiquitous brand name for hydrocodone combined with acetaminophen, was discontinued as a branded product by its manufacturer, but the drug itself never went away. Generic hydrocodone/acetaminophen remains one of the most commonly dispensed prescription opioids in the United States. What changed was not the molecule’s availability but its regulatory classification, the cultural attitude surrounding it, and the sheer volume at which it is prescribed. The story of Vicodin’s “disappearance” is really a story about how the same drug got harder to obtain, how prescribers shifted their habits, and what consequences followed.
The Brand Went Away, the Drug Did Not
AbbVie, the pharmaceutical company that marketed Vicodin, stopped selling the branded product. But because the active ingredients, hydrocodone and acetaminophen, have long been available in generic form from multiple manufacturers, the practical impact on patients was minimal. If your doctor previously wrote “Vicodin” on a prescription pad, the pharmacy was almost certainly already filling it with a generic version. The branded tablets simply became unnecessary in a market flooded with identical generics at lower cost. Other brand names for the same combination, like Norco and Lortab, followed similar trajectories. Today, prescriptions are written for “hydrocodone/acetaminophen” by its generic name, and pharmacies dispense whichever manufacturer’s version they stock.
So when people ask whether Vicodin is “still prescribed,” the accurate answer is that the brand label is gone but the drug it contained is very much alive in clinical use. It is prescribed for moderate to moderately severe pain after surgery, dental procedures, injuries, and in some chronic pain cases, though the volume has dropped substantially over the past decade for reasons that have nothing to do with the brand’s discontinuation.
The 2014 Rescheduling That Changed Everything
The single biggest event in Vicodin’s prescribing history was not the brand’s discontinuation. It was the DEA’s decision in October 2014 to move all hydrocodone combination products from Schedule III to Schedule II under the federal Controlled Substances Act. Before that change, hydrocodone combined with another ingredient like acetaminophen or ibuprofen sat in Schedule III, which meant doctors could phone in prescriptions, authorize refills, and write for larger quantities with relatively little friction. Schedule II drugs, by contrast, require a new written or electronic prescription each time, with no refills allowed. Patients have to see their prescriber or obtain a new prescription for every fill.
The effect was immediate and dramatic. A systematic review covering 24 studies found that hydrocodone combination product prescribing dropped anywhere from about 3% to 66% depending on the setting and population studied. The number of tablets dispensed per prescription fell sharply, and more prescriptions were written for shorter supplies. In a Medicaid population, the share of prescriptions going to shorter durations jumped from roughly 58% to 82% after the schedule change, while the average number of tablets per prescription was nearly cut in half.
1PubMed Central. The Effect of a Federal Controlled Substance Act Schedule Change on Hydrocodone Combination Products Claims in a Medicaid PopulationThe rescheduling accomplished what it was designed to do: it made hydrocodone harder to prescribe casually and harder to obtain in large quantities. But it also set off a chain of unintended consequences that researchers are still tracking.
What Prescribers Switched To
When writing a hydrocodone prescription became more burdensome, many clinicians simply switched to opioids that remained in Schedule III or lower. Tramadol and codeine-containing products, which at the time carried fewer prescribing restrictions, saw sharp increases. A review of the evidence found that tramadol prescribing rose by anywhere from about 3% to 53% across various studies, while codeine-containing products increased by as little as 1% and as much as a staggering 1,353% in one analysis.
2Journal of the American Pharmacists Association. Effects of hydrocodone rescheduling on opioid use outcomes: A systematic reviewThe pattern was especially visible in dentistry, where hydrocodone had been the go-to opioid for post-procedure pain. After the schedule change, dental hydrocodone prescriptions dropped immediately while codeine, oxycodone, and tramadol prescriptions all rose to partially fill the gap.
3PubMed. Impact of Hydrocodone Rescheduling on Dental Prescribing of OpioidsAt a hospital level, the same substitution played out. While total hydrocodone prescriptions fell for both Norco 5/325 and Norco 10/325 formulations, the drop was offset by a dramatic increase in tramadol, Tylenol #3 (codeine/acetaminophen 30/300 mg), and Tylenol #4 (codeine/acetaminophen 60/300 mg), all of which did not carry Schedule II requirements at the time.
4PubMed Central. Change in prescription habits after federal rescheduling of hydrocodone combination productsWhether this substitution made patients safer is debatable. Five studies in the systematic review found that total morphine equivalents, a standardized measure of overall opioid exposure, dropped by at least 10%. But two studies found that morphine equivalents actually increased, likely because the alternative opioids were prescribed in higher doses or longer courses to compensate for the perceived difference in potency. The net result in some settings was more overall opioid exposure, not less, just from different molecules.
2Journal of the American Pharmacists Association. Effects of hydrocodone rescheduling on opioid use outcomes: A systematic reviewThe CDC Guidelines Added Another Layer
Two years after the rescheduling, the CDC released its 2016 Guideline for Prescribing Opioids for Chronic Pain, which recommended against routine opioid use for chronic non-cancer pain and urged prescribers to try non-opioid treatments first. This guideline did not single out hydrocodone; it targeted opioid prescribing broadly. But the cumulative effect was another significant downward push on the kinds of prescriptions that had once gone out as Vicodin.
The guideline was associated with a roughly 20-percentage-point reduction in the rate at which chronic pain patients received at least one opioid prescription, compared with what would have been expected without the guideline. That analysis covered more than 450,000 patients with common chronic pain diagnoses. The reductions applied across pain conditions and did not vary based on the strength of expert consensus against opioid use for a given diagnosis, which suggests that prescribers responded to the guideline’s overall tone rather than weighing each clinical scenario individually.
5PubMed Central. CDC Guideline For Opioid Prescribing Associated With Reduced Dispensing To Certain Patients With Chronic PainIn emergency departments and dental clinics within the VA healthcare system, a similar pattern emerged after the implementation of opioid-prescribing guidelines: statistically significant decreases in the average number of opioids prescribed, total morphine equivalents per prescription, days’ supply, and medication quantity per prescription.
6PubMed Central. Opioid prescribing trends in a Veterans Affairs emergency department and dental clinic before and after implementation of opioid-prescribing guidelinesThe combined effect of the 2014 rescheduling and the 2016 guidelines means that if you visit a doctor today with moderate pain, you are far less likely to leave with a hydrocodone prescription than you would have been in 2013, and if you do get one, it will probably be for fewer pills and fewer days.
How Hydrocodone Works and Why Genetics Matter
Hydrocodone is a semi-synthetic opioid that relieves pain primarily by binding to mu-opioid receptors in the brain and spinal cord. But the drug as swallowed is actually a prodrug in part: a liver enzyme called CYP2D6 converts a portion of it into hydromorphone, a stronger opioid that contributes to the drug’s pain-relieving and euphoric effects. How well your body performs this conversion depends on your genetics.
People who are “extensive metabolizers,” meaning they carry two working copies of the CYP2D6 gene, convert hydrocodone to hydromorphone efficiently. In a study comparing metabolizer types, extensive metabolizers reported more of the pleasant opioid effects and fewer negative effects in the first hour after taking a dose than people who were poor metabolizers or whose CYP2D6 had been blocked by another drug. Poor metabolizers, roughly 5% to 10% of the white population, convert hydrocodone at a negligible rate and may get less pain relief from the standard dose.
7PubMed. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphoneOn the flip side, “ultra-rapid metabolizers” convert the drug faster than average, which can lead to unexpectedly high hydromorphone levels, more sedation, and a higher risk of respiratory depression. This genetic variability is one reason the same Vicodin dose that works well for one person can feel like nothing to another or hit dangerously hard for a third. Pharmacogenomic testing can identify a patient’s CYP2D6 status, though it is not routinely done before a short-term opioid prescription.
The Acetaminophen Problem
One risk unique to hydrocodone/acetaminophen combinations is liver damage from the acetaminophen component. Acetaminophen is safe in recommended doses, but it has a narrow margin between a therapeutic dose and a toxic one. At excessive levels, the liver produces a toxic byproduct called NAPQI, which under normal circumstances gets neutralized by the body’s glutathione stores. When those stores are overwhelmed, NAPQI binds to liver cell proteins, disrupts mitochondrial function, and can trigger acute liver failure.
8Journal of Clinical and Translational Hepatology. Acetaminophen-Induced Hepatotoxicity: a Comprehensive UpdateThis is a particular concern with combination products because patients may not realize their pain pill contains acetaminophen and then take additional over-the-counter acetaminophen on top of it. In 2011, the FDA asked manufacturers to limit the acetaminophen in combination opioid products to 325 mg per tablet, down from the 500 mg or even 750 mg found in some older formulations. Today’s standard hydrocodone/acetaminophen tablets contain 325 mg of acetaminophen, but even so, a patient taking the maximum prescribed dose of several tablets per day while also using Tylenol for a headache can creep into dangerous territory. Heavy alcohol use compounds the risk because it depletes the same glutathione reserves the liver needs to handle NAPQI.
How Hydrocodone Stacks Up Against Alternatives
In head-to-head comparisons for acute pain, hydrocodone combined with ibuprofen performed at least as well as oxycodone combined with acetaminophen. In a trial of patients recovering from obstetric or gynecologic surgery, pain relief scores were similar between the two combinations for the first several hours but then significantly favored the hydrocodone/ibuprofen combination at the five-, six-, seven-, and eight-hour marks.
9Clinical Therapeutics. New Drugs Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of postoperative obstetric or gynecologic painAmong people seeking treatment for opioid addiction, however, hydrocodone and oxycodone together accounted for about 75% of primary drug choices. Oxycodone was preferred by a significantly larger share of users, roughly 45% compared with 29% for hydrocodone, largely because users reported that oxycodone produced a better “high.” Interestingly, hydrocodone users cited the presence of acetaminophen as something that deterred them from escalating their doses, since they feared liver damage from taking too many pills.
10PubMed. Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United StatesThat finding cuts both ways. On one hand, the acetaminophen component may function as a built-in ceiling that discourages recreational dose escalation. On the other, it means that the very thing making the drug somewhat less appealing for misuse is also the thing that causes liver damage if someone ignores the warning and takes too much anyway.
The Shift Toward Non-Opioid Pain Management
Beyond the regulatory and guideline changes, there is a broader clinical movement away from opioids as first-line pain treatment. In surgical settings, Enhanced Recovery After Surgery (ERAS) protocols now emphasize multimodal approaches that combine non-opioid medications, nerve blocks, physical therapy, and other techniques to reduce reliance on opioids like hydrocodone.
11PubMed Central. Enhanced Recovery After Surgery (ERAS) Protocols in Orthopaedic Surgery: Opioids or Not Opioids?For many acute pain scenarios where Vicodin would have been the reflex prescription a decade ago, clinicians now reach for combinations of acetaminophen and ibuprofen taken together (without any opioid), or short courses of stronger anti-inflammatory drugs, sometimes supplemented with gabapentinoids or muscle relaxants depending on the pain type. Opioids like hydrocodone are increasingly reserved for pain that does not respond to those first-line approaches or for the first few days after major surgery. This is a genuine cultural shift in medicine, not just a regulatory one.
Racial Disparities in Who Gets Opioid Prescriptions
One dimension of the prescribing landscape that often goes unnoticed is the longstanding disparity in who receives opioid prescriptions at all. A meta-analysis covering 2011 to 2021 found that Black patients were less likely to receive opioid pain medication than white patients, and Hispanic patients were even less likely. The differences persisted after controlling for pain severity and other factors.
12PubMed Central. Racial Disparities in Opioid Prescribing in the United States from 2011 to 2021: A Systematic Review and Meta-AnalysisA separate analysis of chronic pain management found that these disparities extended beyond prescriptions to specialist referrals. Both Black and Hispanic patients had significantly lower odds of receiving interventional pain referrals and neurosurgical referrals compared with white patients. Regarding opioid therapy specifically, both groups had meaningfully lower odds of receiving opioid treatment even after accounting for sex, pain type, and other treatments received.
13Journal of Pain Research. Exploring Racial Disparities in Chronic Pain ManagementThese disparities predate the rescheduling and the CDC guidelines, and they complicate the narrative around opioid prescribing reform. Efforts to reduce opioid overprescribing are layered on top of a system that was already under-treating pain in minority populations. When across-the-board reductions in opioid prescribing occur, patients who were already less likely to receive adequate pain treatment may be disproportionately affected.
The Danger of Counterfeit Pills
There is one context where the tightening of legitimate Vicodin prescriptions has created a genuinely dangerous gap: the illicit market. As prescription opioids became harder to obtain through legal channels, some people turned to unregulated sources. An ethnographic study at tourist-oriented pharmacies in Mexico found that 70% of pharmacies visited would sell controlled substances without a prescription. Of 45 samples sold as single controlled-substance pills, 18 were counterfeit. While this particular study focused on pills sold as oxycodone and Adderall rather than hydrocodone, the findings illustrate a broader problem: pills sold as “Oxycodone” contained fentanyl in about 30% of samples, and three contained heroin.
14PubMed Central. Fentanyl, Heroin, and Methamphetamine-Based Counterfeit Pills Sold at Tourist-Oriented Pharmacies in Mexico: An Ethnographic and Drug Checking StudyDomestically, counterfeit hydrocodone and oxycodone pills pressed with illicit fentanyl have been a major contributor to overdose deaths. These pills are often visually indistinguishable from legitimate pharmaceutical tablets but may contain wildly inconsistent doses of fentanyl, a synthetic opioid roughly 50 to 100 times more potent than morphine by weight. A person who once took a few Vicodin tablets and seeks to replicate that experience through an unregulated source faces a risk profile that did not exist when the same drug was easily prescribed. This is arguably the most dangerous unintended consequence of the broader shift in opioid access: the people who still want or need opioids but cannot get legitimate prescriptions are being funneled toward a supply chain that is far more lethal than anything that ever came out of a pharmacy.